Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board - Seite 2

 

Stephan Grupp, M.D., Ph.D. is the Novotny Professor of Pediatrics and co-lead of the Abramson Cancer Center pediatrics program at the University of Pennsylvania Perelman School of Medicine. He also serves as the Section Chief of Cellular Therapy and Transplant in Division of Oncology, Director of the Cancer Immunotherapy Program, and Medical Director of the Cell and Gene Therapy Lab at the Children’s Hospital of Philadelphia. His primary area of clinical research is the use of CAR T and other engineered cell therapies in pediatric cancers and other disorders such as sickle cell disease. He led all of the pediatric/young adult ALL trials of CTL019, now approved by the U.S. Food and Drug Administration as Kymriah (tisagenlecleucel), as well as the global registration trial for CTL019 (NEJM 2013, 2014, 2018). His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers. Over 200 scientific publications have been generated by Dr. Grupp’s research, and he has received numerous achievement and impact awards for his contributions to the cell therapy and oncology fields, including his election to the National Academy of Medicine in 2019. Dr. Grupp received his M.D. and his Ph.D. from the University of Cincinnati College of Medicine and completed multiple fellowships at Harvard Medical School, Boston Children’s Hospital, the Dana Farber Cancer Institute and Children’s Hospital and Brigham and Women’s Hospital.

The new advisors join existing SAB members, Chairman Ton Schumacher, Ph.D., Donald B. Kohn, M.D., Malcolm K. Brenner, M.D., Ph.D., Matthew Porteus, M.D., Ph.D., Owen Witte, M.D., Stephen J. Forman, M.D., and Wendell Lim, Ph.D.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.